Early Translational I
Return to Grants
CIRM Early Translational Research Awards
The CIRM Early Translational Research Awards are designed to move promising basic research in stem cell science toward the clinic. These awards will support two categories of projects including research that: 1) results in a development candidate that meets an unmet medical need; or 2) addresses a significant bottleneck in the translation of stem cell biology that hinders advancement of effective, novel cell therapies to the clinic.
FORMS AND INSTRUCTIONS:
All Principal Investigators planning to apply for a CIRM Early Translational Research Award must be officially nominated on a Candidate Nomination Form (CNF) by their host institution and must notify CIRM in a Letter of Intent (LOI). The forms for the CNF and LOI can be accessed through the links below. The Candidate Nomination Form (in hard copy) and the Letter of Intent (as an email attachment to: Early_Translational_LOI@cirm.ca.gov) must be received by CIRM no later than 5:00pm PDT on October 15th , 2008. No exceptions will be made.
APPLICATION INSTRUCTIONS AND FORMS
Application forms will be available online by September 17, 2008. Applications must be received by CIRM no later than 5:00pm PST on November 20th, 2008. No exceptions will be made. Applications will only be accepted from PIs who 1) have been officially nominated on a CNF from their home institution and 2) have submitted a LOI that was accepted by CIRM.
- Application and Instruction Forms
Schedule of Receipt Anticipated Review
ICOC Approval:
April 29, 2009
Awards
| Institution |
Investigator |
Grant Title |
Award Value |
| BioTime, Inc. | Dr. Michael D West Ph.D. | Addressing the Cell Purity and Identity Bottleneck Through Generation and Expansion of Clonal Human Embryonic Progenitor Cell Lines |
$4,721,706 |
| University of California, Davis | Dr. Alice F Tarantal | In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies |
$3,143,392 |
| Salk Institute for Biological Studies | Dr. Inder M. Verma | Curing Hematological Diseases |
$5,979,252 |
| Sanford Burnham Prebys Medical Discovery Institute | Dr. Evan Y. Snyder | Developmental Candidates for Cell-Based Therapies for Parkinson’s Disease (PD) |
$5,190,752 |
| Stanford University | Dr. Jill Helms | Enhancing healing via Wnt-protein mediated activation of endogenous stem cells |
$6,464,126 |
| Jackson Labs | Pali G. Kaur | Mouse Models for Stem Cell Therapeutic Development |
$3,759,134 |
| Gladstone Institutes, J. David | Dr. Warner C Greene | Maximizing the Safety of Induced Pluripotent Stem Cells as an Infusion Therapy: Limiting the Mutagenic Threat of Retroelement Retrotransposition during iPSC Generation, Expansion and Differentiation |
$1,280,001 |
| Scripps Research Institute | Dr. Martin Friedlander | Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration |
$5,806,321 |
| University of California, Los Angeles | Dr. Gabriel H. Travis | Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration |
$5,487,136 |
| Scripps Research Institute | Dr. Jeanne F Loring | Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation |
$5,830,771 |
| ViaCyte, Inc. | Dr. Olivia G. Kelly | Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product |
$5,405,397 |
| Scripps Health | Dr. Darryl D. D’Lima | Stem Cell-Based Therapy for Cartilage Regeneration and Osteoarthritis |
$3,118,431 |
| University of California, Irvine | Dr. Frank LaFerla | Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease |
$3,599,997 |
| University of California, Davis | Dr Jan A Nolta | Sustained siRNA production from human MSC to treat Huntingtons Disease and other neurodegenerative disorders |
$2,615,674 |
| University of California, San Diego | Dr. Yang Xu | Developing induced pluripotent stem cells into human therapeutics and disease models |
$5,165,028 |
| Parkinson’s Institute | Mr. James “Bill” William Langston Mr. | Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson’s disease research and drug discovery |
$3,698,646 |
| | | Total:
$71,265,763.14 |
